{"disease":{"id":"excess-subcutaneous-fat","name":"Excess subcutaneous fat","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"deoxycholic-acid","indication_name":"Excess subcutaneous fat","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kybella","generic_name":"DEOXYCHOLIC ACID","company_name":"AbbVie","drug_phase":"marketed","molecular_target":"G-protein coupled bile acid receptor 1","drug_class":"Cytolytic Agent [EPC]","quality_score":65,"revenue":null,"mechanism":"Kybella works by targeting and destroying excess fat cells through a process that involves disrupting the cell membrane."},{"drug_id":"kybella","indication_name":"Excess subcutaneous fat","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Kybella","company_name":"Massachusetts General Hospital","drug_phase":"marketed","molecular_target":"G-protein coupled bile acid receptor 1, fMet-Leu-Phe receptor, Bile acid receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}